Summary

Infliximab was the first anti—tumor necrosis factor a monoclonal antibody approved for the treatment of rheumatoid arthritis (RA). In 2013, CT-P13 was the first infliximab biosimilar agent approved by the European Commission. This Phase 3 trial of BOW-015 is the first study to compare an infliximab biosimilar agent with infliximab in patients with RA, assessing time points before Week 14.